Indegene Limited Share Price

Equities

INDGN

INE065X01017

Business Support Services

Market Closed - NSE India S.E. 05:10:30 19/06/2024 pm IST 5-day change 1st Jan Change
569.9 INR -2.07% Intraday chart for Indegene Limited -2.31% 0.00%
Sales 2022 16.65B 200M Sales 2023 23.06B 277M Capitalization 129B 1.55B
Net income 2022 1.65B 19.76M Net income 2023 2.66B 31.91M EV / Sales 2022 * -
Net cash position 2022 * - 0 Net cash position 2023 * - 0 EV / Sales 2023 * -
P/E ratio 2022 *
-
P/E ratio 2023 *
-
Employees 5,181
Yield 2022 *
-
Yield 2023 *
-
Free-Float 30.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.07%
1 week-2.31%
Current month+9.42%
1 month+5.77%
More quotes
1 week
562.70
Extreme 562.7
616.95
1 month
470.10
Extreme 470.1
616.95
Current year
452.00
Extreme 452
660.00
1 year
452.00
Extreme 452
660.00
3 years
452.00
Extreme 452
660.00
5 years
452.00
Extreme 452
660.00
10 years
452.00
Extreme 452
660.00
More quotes
Indegene Limited is a life sciences commercialization company. It provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical devices companies. The Company operates through four segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Its Enterprise Commercial Solutions segment primarily involve assisting life sciences companies with their digital marketing operations. Its Omnichannel Activation solutions segment help life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Under its Enterprise Medical Solutions segment, it establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. Others segment offers enterprise clinical solutions and consultancy services.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
582
Average target price
-
Consensus